The data presented on this specific topic are limited but do show that chemotherapy for ovary cancer can be effective, although the prognostic significance of the disease at presentation is poor. Data from a recent study of other studies may indicate that, with modern chemotherapy, the disease can be controlled, and the survival of cancer patients is significantly increased.
Ovarian carcinomas are a type of cancer that can arise in many parts of the body and pose serious health risks. They are often caused by the gradual accumulation of multiple genetic abnormalities over many years or by unknown causes. Women affected by this disease have many different signs and symptoms which change throughout their lives. If left untreated, ovarian cancers can grow and invade many parts of the body and cause a decrease in quality of life and life expectancy. It is important that they find as early a diagnosis as they can as soon as they can.
The most common symptoms of [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) are persistent, non-specific abdominal conditions such as chronic diarrhea and nausea. Ovary cancer may manifest itself as the presenting symptom of an abdominal mass (particularly a malignant tumor such as ovarian carcinoma, but also a non-cancerous condition such as a fatty mass). The most-common symptoms of ovarian cancer in women are pelvic pain, bloating, pelvic mass or swelling. Other major signs are tiredness, weight loss, or swelling of the face or in the neck, which may occur due to a recurrence of cancer, or due to metastasis to the cervical lymph nodes, and should result in prompt medical treatment.
Endometrium (the inner lining of the uterus) is the single most common site of [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) (85%) in postmenopausal women. Ovarian cancer typically presents in middle-aged women and is diagnosed in 10% of all gynaecological cancers with an increased incidence of ovarian carcinoma (about 1%) every 20 to 50 years. The prognosis of ovarian cancer is often poor. Ovarian cancer is estimated to have a 5 year survival rate of less than 25%, although survival rates have improved since the introduction of chemotherapy regimens in the 1950s. In this article, ovarian cancer will be treated in reference to its various histological subtypes, location, stage, treatment modality, and prognosis.
Ovary cancer is more common among younger women than the American Cancer Society or the National Cancer Institute estimates. The incidence of ovarian cancer increased as age increased. Findings from a recent study, about half of the women who developed ovarian cancer had been under 45 years of age.
Standard treatments for [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) include surgery, chemotherapy, radiotherapy, and fertility removal. While surgery is a common part of ovarian cancer treatments, its role in overall cancer-free survival is limited. In addition, many chemotherapy regimens have long, painful cycles. Radiation therapy and fertility removal are not usually part of treatment unless there has been metastasis, cancer of a solid organ (cancer in the pleura, lung, brain, bones, liver, kidney, or other major organs), or recurrent ovarian cancer. One of the best treatment options is to combine surgery with standard chemotherapy for the treatment of ovarian cancer. [More about this treatment option can be found here: Ovarian cancer and adjuvant chemotherapy(https://www.ncbi.
Ovary cancer patients with synchronous and/or metastatic ovarian cancer have a high mortality rate. There was no survival advantage seen using chemotherapy for patients with early stage disease. Patients with advanced stage disease have a higher mortality rate compared with patients with early stage disease. Although a more aggressive approach should improve survival, patients might not benefit from this approach if they are candidates for more complex surgery and adjuvant chemotherapy, the current standard of care.
Female fertility-associated agents that have long been suspected of driving high rates of [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) also do so in the presence of an increased level of cancer. The most likely explanation for this is a high cancer burden resulting from long-term exposure to ovarian hormones. Thus, the relative risks of ovarian cancer associated with fertility-related factors are significantly higher in the presence of a high cancer burden, compared with their respective values when there is a low level of cancer. This may explain why ovarian cancer is among the most common malignancies of reproductive-aged women globally.
Patient interest and willingness to participate in clinical trials of ovary cancer therapies are related to patient characteristics. Age and education were associated with [participation and willingness to participate of eligible patients in clinical trials of ovarian cancer treatments(http://www.clinicaltrials.gov/ct2/show/NCT01513990)].
Niraparib treatment was well tolerated in this phase III study. No increased risk of grade 3/4 haematologic toxicity was seen with treatment. Although treatment-related adverse events included nausea and fatigue, there were not enough complete responders to report with certainty. Data from a recent study were similar to that for those previously reported and there were no clear differences in either overall ORR, PFS or OS.
Approximately 27,000 new cases of ovarian cancer are diagnosed in the US every year. Overall, people with ovarian cancer typically have a 5 year survival rate of 75%. This is less than that of breast cancer, which is an aggressive disease with lower survival rates. Overall, about 25,000 women die of ovarian cancer each year. The average age of menopausal onset is about age 50 in industrialized countries.\n\n- Ovarian cancer"
In a recent study, findings did not find an association between BMI and stage, grade of disease, or outcome at staging examinations in patients with stage I to III ovarian cancer. Because patients should be treated as equals, with an equal level of care for all patients, and regardless of their BMI, we do not believe that patients should be prohibited from surgery if their health permits (including BMI).